Veregen Pregnancy Warnings
This drug should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
US FDA pregnancy category: C
Animal studies have failed to reveal evidence of teratogenicity or fetal harm. In the presence of maternal toxicity, subcutaneous doses of 12 and 36 mg/kg/day from gestational days 6 to 19 resulted in reduced fetal body weights and delays in skeletal ossification. A pre- and post-natal development study in rats using vaginal administration of 0.10 and 0.15 mL/rat/day resulted in increased mortality of the dams, associated with indications of parturition complications; an increased incidence of still births was also observed (0.15 mL/rat/day dose only). There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
See references
